Understanding predictors of recurrent hyperkalemia may help health care providers provide a more individualized approach to hyperkalemia management. Hyperkalemia recurrence is more likely in patients ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

A recent population-based study assessed the incidence of clinically significant hyperkalemia among adult CKD patients being treated with RAASis and how this affected future treatment. In the study, 9 ...

New findings have important implications in the new era where delaying dialysis initiation is a priority goal by means of continued conservative management of hyperkalemia, according to investigators.

Synthetic ion-exchange resins were first made available to industry in 1935 and have since been extensively adapted to . . . From the Cardio-Renal Laboratory, Second (Cornell) Medical Division, ...

Please provide your email address to receive an email when new articles are posted on . During study follow-up, 93 patients developed kidney failure with replacement therapy and 134 patients died.

If you have hyperkalemia -- high levels of potassium -- your treatment will depend on how high your levels have risen, how quickly it happened, and whether you have serious symptoms. Severe ...

Please provide your email address to receive an email when new articles are posted on . After reviewing patient resources on low-potassium diets for the management of hyperkalemia in chronic kidney ...

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent ...